03 The Global Diabetes Care Market CMD2011

Novo Nordisk Capital Markets Day
5 May 2011
The global diabetes care market

Kre Schultz COO
5 May 2011
Slide no 2
Forward-looking statements
Novo Nordisks reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the companys Annual Report 2010 and Form 20-F, both expected to be filed with the SEC in February 2011 as well as this document and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as believe, expect, may, will, plan, strategy, prospect, foresee, estimate, project, anticipate, can, intend, target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: - statements of plans, objectives or goals for future operations, including those related to Novo Nordisks products, product research, product development, product introductions and product approvals as well as cooperations in relation thereto, - statements containing projections of or targets for revenues, income (or loss), earnings per share, capital expenditures, dividends, capital structure or other net financials, - statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and - statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisks products, introduction of competing products, reliance on information technology, Novo Nordisks ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees and failure to maintain a culture of compliance. Please also refer to the overview of risk factors in Risk management of the Annual Report 2010 available as of 4 February 2011 on the companys website (novonordisk.com). Unless required by law Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.
5 May 2011
Slide no 3
Capital markets expect diabetes care to continue to outgrow the general pharmaceutical industry
Growth in global prescription sales versus diabetes care sales (CAGR)
Total Prescription sales Diabetes Care sales Insulin and GLP-1 sales
18.4% 15.9% 12.3% 10.7% 12.0% 9.2% 6.4% 3.6% 7.8%
2000-2005
2005-2010
2010-2015
Source: EvaluatePharma, data retrieved January 21, 2011
5 May 2011
Slide no 4
Diabetes market development

Global diabetes care market by treatment class
DKK billion 200
180 160 140 120
200
Global insulin market by segments

tMU
400
OAD
Insulin
GLP-1
Total market: CAGR 11.4% Injectables: CAGR 15.6%
350 300
CAGR volume: 7.1% CAGR value*: 14.3% 34%
250
Fast acting 31% Premix 35% 30%
100 80 60 40 20
CAGR 14.3%
150 100
CAGR 7.8%
Feb 2006
Note: Monthly MAT, value figures Source: IMS
50 0
34%
Feb 2006
Long acting
36%
Feb 2011
Feb 2011
Note: *in DKK. Monthly MAT, volume figures Source: IMS
5 May 2011
Slide no 5
Sustained double-digit insulin market growth

Global insulin market growth 2006-2011
DKK billion 100
The fundamental growth drivers of the insulin market Volume Prevalence of diabetes Diagnosis rates and treatment rates Intensification of insulin regimens Growing BMI Life-length
86.7 bDKK
80
20.7 bDKK 21.6 bDKK 44.4 bDKK
60
40
Value Conversion to new generations of insulin Device penetration Price changes
20
0 MAT Feb 2006 Volume contribution Mix/price contribution MAT Feb 2011
Source: IMS, Monthly MAT, value figures
5 May 2011
Slide no 6
Globally, diabetes has become an epidemic - driven by lifestyle changes and demographics
Estimated number of people with diabetes projections appear conservative
Million people
Diagnosis and optimal treatment remains a challenge the rule of halves

100%
450 400 350 300 250 200 150 100 50 0

CAGR: 6.6%
CAGR: 2.2%
439
All people with diabetes

285
International Operations
151
JP, Korea Europe
China Japan Europe North America
50% are diagnosed

50% have access to care
50% get decent care
50%
25% 12%
2000
2010
N. America 2030
//
50% reach target
Source: International Diabetes Foundation: Diabetes Atlas, 2000 and 2009 Note: Data covers the 20-79 age-group. IO: International Operations, Japan includes Korea
5 May 2011
Slide no 7
The world is growing unhealthier

Prevalence of overweight and obesity in selected countries
90%
Proportion of overweight and obese of population (%)
United States Canada England France Italy
80% 70% 60% 50% 40% 30% 20% 10% 0% 1970 1980 1990 2000 2010 2020
Adapted from: Sassi, F. et al. 2009 The Obesity Epidemic: Analysis of Past and Projected Future Trends in Selected OECD Countries, OECD Health Working Papers, No. 45, OECD Publishing. Available at: http://www.ecoclimax.com/2010/10/past-and-projected-future-overweight.html
5 May 2011
Slide no 8
Life expectancy has on average risen by 4 months each year since 1970
Life expectancy at birth (weighted average)
69 years 56 years
1970
2010
Source: www.nationmaster.com, CIA world fact book
5 May 2011
Slide no 9
Life expectancy has on average risen by 4 months each year since 1970
Life expectancy at birth (weighted average)
82 years? 69 years 56 years
1970
2010
2050
Source: www.nationmaster.com, CIA world fact book
5 May 2011
Slide no 10
Implied development in insulin consumption

Insulin consumption in selected countries average insulin units per inhabitant
United States Germany United Kingdom Japan China
426 349 293
238
264
165 99 53 1 2000 2010 14
Sources: Calculation based on IMS volume figures and United Nations Population Division demography data
5 May 2011
Slide no 11
Modern insulin is replacing human insulin as human insulin replaced animal insulin
Share of total insulin volume
100%
80%
Modern insulin
60%
Human insulin
40%
20%
0% 1994
Animal insulin
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Source: IMS, annual volume figures
5 May 2011
Slide no 12
Modern insulin constitute more than 80% of the total insulin value market
Share of total insulin value
100%
80%
Modern insulin
60%
40%
Human insulin Human insulin
20%
0%
Animal insulin Animal insulin

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
1994
Source: IMS, monthly MAT value figures
5 May 2011
Slide no 13
Two-thirds of insulin volume is injected via a modern pen device

Share of total insulin volume 100%
Prefilled device
80%
60%
Durable device
40%
Vial and syringe

20%
0% 1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
Source: IMS, annual volume figures
5 May 2011
Slide no 14
Characteristics of the insulin industry

Chronic disease leading to life-long patient-drug relationship Significant and growing patient population Continuous upgrade of insulin treatment Significant usage of modern pen devices Strong brand loyalty and limited switching between therapies Many prescribers requiring significant commercial operations High volume production with significant capital investment required Limited abbreviated regulatory pathways for approval of biosimilar insulin
Significant growth
Complex to be competitive
5 May 2011
Slide no 15
Novo Nordisk device development for improved insulin treatment

1923 - 1985 1985 - 2010
5 May 2011
Slide no 16
Diabetes is chronic disease leading to long patient-drug relationship

Insulin treatment is generally characterised by strong brand loyalty and limited switching between therapies
12 years
Insulin treatment
74 years
8 years 54 years
OAD treatment
Average life expectancy with type 2 diabetes
Diagnosis of type 2 diabetes
Sources: Calvert MJ, McManus RJ, Freemantle N (2007) Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care retrospective cohort study Br J Gen Pract 57: 455-60. The British Journal of Diabetes & Vascular Disease 2008 8:92. 2005 -2008 National Health and Nutrition Examination Survey. http://www.newsobserver.com/2011/03/03/1025677/type-2-diabetes-linked-to-shorter.html#storylink=misearch. Lifeexpectancy in Individuals with type 2 Diabetes, Diabetes (2007); 56: (supp1): A596
5 May 2011
Slide no 17
Novo Nordisk has significant operations across the world to remain competitive
North America: ~4,000 FTEs
Europe: ~3,100 FTEs
Japan & Korea: ~900 FTEs
China: ~2,100 FTEs
International Operations: ~2,700 FTEs
FTEs represent full-time employee equivalents in Novo Nordisks sales regions (excludes a.o. employees in headquarter and manufacturing)
5 May 2011
Slide no 18
Insulin manufacturing process
API: insulin crystals
F&F: liquid form
Device & packaging
Fermentation
Recovery
Purification
Formulation
Filling
Assembly
Packaging
5 May 2011
Slide no 19
Novo Nordisks global manufacturing setup
API production Formulation & filling Assembly Packaging Device & needle manufacturing
Denmark
Formulation & filling Assembly Packaging
Clayton
Chartres
Tianjin
Koriyama
Packaging
Device manufacturing Packaging Filling plant project
Montes Claros
5 May 2011
Slide no 20
Novo Nordisk has sustained a global insulin market leadership position

Insulin value market share worldwide
Novo Nordisk Sanofi-Aventis Eli Lilly Others
Insulin volume market share worldwide

70% 60% 50% 40% 30%
70% 60%
51% 44% 33% 22%

20% 10% 20% 10% 50% 40% 30%
23% 22% 4%
Feb 2006 Feb 2011
1%
0%
Feb 2006 Feb 2011
0%
Source: IMS Monthly MAT, value figures
Source: IMS Monthly MAT, volume figures
5 May 2011
Slide no 21
through focus on improvements for patients

Modern insulin global volume market share
Prefilled device global insulin volume market share

FlexPen SoloStar KwikPen
70% 60% 50% 40% 30% 20% 10%
30%
46% 34%
20%
19%
19%
10%
10%
1%
0%
Feb 2006 Feb 2011
3%
0%
Feb 2006 Feb 2011
5 May 2011
Slide no 22
with a strong portfolio of modern insulins

Strong current portfolio
20%
Novo Nordisks modern insulins global insulin volume market share

NovoMix NovoRapid Levemir
14% 9% 6%
10%
0%
Feb 2006
Feb 2011
5 May 2011
Slide no 23
Novo Nordisk is now also expanding into earlier treatment and growing the GLP-1 class
Victoza is driving the expansion of the global GLP-1 market
GLP-1 sales in bDKK (right axis)
5%
North America constitutes the majority of the GLP-1 value market*

DKK billion 7
6
Rest of world Europe
Diabetes market share (value)
4%
Victoza
3%
26%
4 3
2%
72%
exenatide
1%
2 1
North America
0%
Feb 2006
0 Feb 2011
Source: IMS Monthly MAT, value figures (DKK)
*Annual value of diabetes market MAT February 2011 Source: IMS, Monthly value data (DKK)
5 May 2011
The diabetes care market in the US

Jurek Gruhn SVP Region North America
5 May 2011
Slide no 25
Outline
The diabetes challenge Treatment of diabetes today Victoza performance Insulin market performance Focus areas and priorities
5 May 2011
Slide no 26
Today, diabetes affects more than 32 million Americans

Increasing prevalence of diabetes 2010: ~32 million 2015: ~40 million 2025: ~53 million
<6%
6-7%
8-9%
10-11%
12-13%
14-15%
16-17%
18-19%
Note: Improvements in therapies and medical management over time are factored in. Sources: CDC Behavioral Risk Factor Surveillance System; Narayan, Impact of Recent Increase in Incidence on Future Diabetes Burden, Diabetes Care 2006;29:2114-2116; Boyle, Projection of the year 2050 burden of diabetes in the US adult population, http://www.pophealthmetrics.com/content/8/1/29; Institute for Alternative Futures projections
5 May 2011
Slide no 27
Associated costs of diabetes represent a significant and increasing economic burden for society
Total annual direct medical and indirect societal costs of diabetes (billion USD) 2010: 299 bUSD 2015: 374 bUSD 2025: 514 bUSD
36 bUSD 30 bUSD 21 bUSD
<1b
1-2.9b
3-4.9b
5-9.9b
10-14.9b
15-24.9b
>25b
Sources: CDC Behavioral Risk Factor Surveillance System; Narayan, Impact of Recent Increase in Incidence on Future Diabetes Burden, Diabetes Care 2006;29:2114-2116; CDC, 2010 National Diabetes Fact Sheet; Boyle, Projection of the year 2050 burden of diabetes in the US adult population, http://www.pophealthmetrics.com/content/8/1/29; Institute for Alternative Futures projections
5 May 2011
Slide no 28
Treatment of diabetes in the US today

Share of patients by treatment class
Rapid-only 14% Premix-only 14% Basal-Bolus 29%
Insulin 24% Incretin 10%
OAD - Met/SU/TZD 55%
Basal-only 40% GLP-1 - 20%
Diet & Exercise 11%
DPP-4s 80%
Note: Insulin data include treatment with concomitant non-insulin products Source: IMS LRx Monthly Regime, 12/10 PROJECTED to Mattson Jack, NHANES IV and Ropers 2010
5 May 2011
Slide no 29
In the US, the insulin market is outgrowing the overall diabetes care market
US diabetes care market by treatment class
DKK billion 120 OAD Insulin GLP-1 tMU
120
US insulin volume market by segments

CAGR volume: 5.8% CAGR value*: 18.9%
100
Total market: CAGR 12.0%
100
80
80
Fast acting Premix
60
60
40
CAGR 18.9%
40
20
CAGR 5.6%
Feb 2006 Feb 2011
20
Long acting
Feb 2006 Feb 2011
Note: * in DKK. Monthly MAT, volume figures Source: IMS
5 May 2011
Slide no 30
Victoza continues to drive GLP-1 growth

Expansion of the GLP-1 market
GLP-1 TRx scripts (thousands) 300 GLP-1 % of of diabetes market value (right axis) Number of patients (thousands)
6%
5
Victoza source of patients
250
5%
200
Victoza
4%
3
exenatide DPP-IV TZD met Insulin
150
3%
2
SU met Metformin
100
exenatide
2%
64%
50
1%
Nave
0
Mar 2010
Mar 2011
0%
Mar 2010
Mar 2011
Source: IMS, NPA Monthly data; IMS LRx Weekly Data
Note: Nave is defined as all patients who have not filled a prescription in 12 months Source: IMS, NPA Monthly data; IMS LRx 4 week average Naive and Switch/Add Script Counts
5 May 2011
Slide no 31
Volume growth and value upgrade drive insulin market value expansion
US insulin value market growth
DKK billion 60 Penetration of total market 80%
70% 60%
Value upgrade
Modern insulin penetration
73%
50
40
18.5 bDKK
50% 40% 30%
30 20
9.0 bDKK
Device penetration
27%
10 0
19.9 bDKK
47.4 bDKK
20% 10% 0%
February 2006 Volume growth
Mix/price growth
February 2011
Feb 2006
Feb 2011
Note: Monthly MAT, volume figures Source: IMS
5 May 2011
Slide no 32
Novo Nordisk has increased overall insulin market share in the US

US total insulin volume market share
Novo Nordisk
70% 60% 50% 40%
US total insulin value market share

Novo Nordisk Sanofi-Aventis Eli Lilly
Sanofi-Aventis
Eli Lilly
70% 60% 50% 40%
42% 32%
37% 37% 26%
30% 20% 10% 0%
30%
26%
20% 10% 0%
Feb 2006
Feb 2011
Feb 2006
Feb 2011
Note: Monthly MAT, value figures (DKK) Source: IMS
5 May 2011
Slide no 33
Novo Nordisk has increased modern insulin market share in the US

US modern insulin volume market share
US modern insulin value market share

70% 60% 50% 40% 30% 20% 10% 0%
70% 60% 50%
44% 37%
42%
40% 30% 20% 10% 0%
37% 21%
19%
Feb 2006
Feb 2011
Feb 2006
Feb 2011
Note: Monthly MAT, value figures (DKK) Source: IMS
5 May 2011
Slide no 34
Insulin market shares and dynamics

US total insulin market shares by segment
Novo Nordisk Sanofi-Aventis Eli Lilly Conversion rate to modern insulin
100%
Short acting segment
100%
Premix segment
100%
Long acting segment
Insulin market share (volume)
80%
80%
80%
60%
60%
60%
40%
40%
40%
20%
20%
20%
0%
Feb 2006
Feb 2011
0%
Feb 2006
Feb 2011
0%
Feb 2006
Feb 2011
Source: IMS, Monthly MAT volume figures
5 May 2011
Slide no 35
Focus areas for the US

Expand Victoza prescribing base and access Continue modern insulin strategy of value creation by balancing profitability and access Preparing for a successful launch of Degludec and DegludecPlus
5 May 2011
The diabetes care market in China

Ron Christie SVP Region China
5 May 2011
Slide no 37
China is evolving as the worlds #3 pharma market

2009 Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 United States Japan France Germany China Italy Spain United Kingdom Brazil Canada Russia Turkey India Mexico South Korea Australia Greece Venezuela Netherlands Poland 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2011 Rank United States Japan China Germany France Italy Spain Brazil United Kingdom Canada Russia India South Korea Venezuela Mexico Australia Turkey Greece Poland Netherlands 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2013 Rank United States Japan China Germany France Italy Spain Brazil Canada United Kingdom Russia Venezuela India South Korea Turkey Mexico Australia Greece Poland Belgium
Source: IMS Health MIDAS, Market Prognosis October 2009. Market size ranking in constant USD
5 May 2011
Slide no 38
This growth has been driven by five major factors

Chinas pharmaceutical market is estimated to grow 20% per annum 2010-2015
World #2 economy in 2010 8% GDP growth for the next 5 years (government target 7.5%) 2006-2010: +46 million >50 years old 2010-2020: +180 million more Latest study estimates 92 million people with diabetes Obese population tripled from 2002 to 2010 Broaden coverage and benefits Strengthen primary care and rural healthcare services Improve disease prevention and early diagnosis Increasing M&A activity
Robust economic growth
Ageing population
Increasing incidence of chronic diseases
Sweeping healthcare reforms
Increased investment from all players
Source: IMS RDPAC presentation March 2011
5 May 2011
Slide no 39
Substantial growth in diabetes prevalence expected in the BRIC countries

Driven by prevalence growth in the BRIC countries
Million people 100
Diagnosis, treatment intensification and regional difference remains key challenges

% of people with diabetes 100
2010 2030
80
87
80
64
60
51 44
60
40
40
30%
24% 3%
20
8
0
13
10
10
20
0
Brazil Russia India China
People with diabetes
Diagnosed diabetics
Treated diabetics
Patients achieving targets
Source: International Diabetes Foundation: Diabetes Atlas, 2000 and 2009 Note: Data covers the 20-79 age-group. IO: International Operations, Japan includes Korea
5 May 2011
Slide no 40
Changing Diabetes in China - increasing awareness and diagnosis

Insulin Patient Self-management Guideline, CDS-NN Changing Diabetes bus: 3 years, 61 cities, 46,000 patients and ~200 media reports 12 more cities will be covered in 2011 Diabetes knowledge websites for both patients and physicians GDM program: 3-year, World Diabetes Foundation-Ministry of Health-Novo Nordisk programme: Establish 45 centres, train 4,725 physicians and screen 292,500 women Localised Barometer Programme Diabetes Care Campaign: Covered 90 hospitals + 200 CHC, 45,952 patients screened, 1,690 physicians and nurses educated Social Network for Endocrinologists in China & Medical Information Website: launched in Feb 2011 Leadership foras NNDU NovoCare serving more than 600,000 members since 2011 Provide comprehensive diabetes knowledge for patients and organise a variety of patient activities 24-hour hotline service - >9000 calls per month Patients follow-up calls to ensure successful insulin initiation - >66,000 calls per month
5 May 2011
Slide no 41
Novo Nordisk is the company with the largest focus on diabetes care in China
A total of 3,375 employees across Commercial operations in China Manufacturing R&D Hong Kong Taiwan
Heilongjiang Jilin Xinjiang Gansu Inner Mongolia Changchun
Tibet
Liaoning Beijing Shenyang Tianjing Hebei Ningxia Qinghai Shanxi Jinan Shandong Shanxi Henan Jiangsu Shanghai Hubei Chongqing Anhui Sichuan Wuhan Zhejiang Guizhou Hunan Jiangxi Yunnan Guangxi Guangdong Fujian Guangzhou Taiwan Hong Kong
Branch Office Frontiers
Hainan
5 May 2011
Slide no 42
The Chinese insulin market is expanding significantly predominately driven by the premix segment
Chinese diabetes care market by treatment class by value
DKK billion 6 OAD Insulin GLP-1 tMU
24
Chinese insulin market by segments
Total market: CAGR 32.4%
20
CAGR volume: 26.8% CAGR value*: 38.8%

23%
16
4
12
Fast acting
CAGR 38.8%
64% 33%
Premix
CAGR 27.8%
1
53% 14% Feb 2006
Feb 2006
Feb 2011
Long acting
13% Feb 2011
Note: Monthly MAT, value figures. IMS projects the Chinese market based on hospital data from 14% of Chinese hospitals Source: IMS
Note: *in DKK. Monthly MAT, volume figures. IMS projects the Chinese market based on hospital data from 14% of Chinese hospitals Source: IMS
5 May 2011
Slide no 43
Novo Nordisk is leading the total diabetes market in China

Total diabetes care value market shares
40%
Novo Nordisk Bayer-Schering Sanofi-Aventis Eli Lilly Bristol Myers-Squibb
Total insulin volume market shares

37%
70% 60%
Novo Nordisk Shanghai Fosun Sanofi-Aventis Tonghua Dongbao Eli Lilly
63%
30%
50% 40%
20%
15%
10%
30% 20%
9% 6%
13%
10% 0%
0%
4%
Feb 2011 Feb 2006
12% 5% 4%
Feb 2011
Feb 2006
Source: IMS Monthly MAT, value figures. IMS projects the Chinese market based on hospital data from 14% of Chinese hospitals
Source: IMS Monthly MAT, volume figures. IMS projects the Chinese market based on hospital data from 14% of Chinese hospitals
5 May 2011
Slide no 44
and maintaining clear leadership in the significant human insulin market

Human insulin value market share
Novo Nordisk Tonghua Dongbao Eli Lilly
Human insulin volume market share

Novo Nordisk Tonghua Dongbao Eli Lilly
90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

Feb 2006
90%
76%
80% 70% 60% 50% 40% 30%
74%
17% 6%
Feb 2011
20% 10% 0%
Feb 2006
17% 8%
Feb 2011
Source: IMS Monthly MAT, value figures.
5 May 2011
Slide no 45
and maintaining a very solid leadership position in the modern insulin market
Modern insulin value market share
Novo Nordisk Sanofi-Aventis BJ Ganli Pharm
Modern insulin volume market share

Novo Nordisk Sanofi-Aventis BJ Ganli Pharm
90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

Feb 2006
Eli Lilly
90% 80% 70%
Eli Lilly
69%
53%
60% 50%
32%
40% 30% 20%
8% 6%
Feb 2011
10% 0%
Feb 2006
15% 11% 4%
Feb 2011
5 May 2011
Slide no 46
Outlook for Novo Nordisk in China

Continue to collaborate with public authorities on diabetes awareness programmes Continue to be the main source of information on diabetes to doctors Continue to be the leading patient support company in the diabetes field Expand operations further into smaller cities and rural areas Launch of Victoza in second half of 2011
5 May 2011
Closing remarks
Kre Schultz COO
5 May 2011
Slide no 48
Innovation is the key to sustained growth
Diabetes
Modern insulins Victoza
Degludec* DegludecPlus*
IDegLira* FIAsp*
Liraglutide in pre-diabetes and obesity
*Note: Degludec is the internal designation for insulin degludec. DegludecPlus is the internal designation for insulin degludec/insulin aspart. IDegLira is the internal designation for insulin degludec/liraglutide. FIAsp is the internal designation for fast acting insulin aspart.
5 May 2011
Slide no 49
Capital markets expect diabetes care to continue to outgrow the general pharmaceutical industry
Growth in global prescription sales versus diabetes care sales (CAGR)
Total Prescription sales Diabetes Care sales Insulin and GLP-1 sales
18.4% 15.9% 12.3% 10.7% 12.0% 9.2% 6.4% 3.6% 7.8%
2000-2005
2005-2010
2010-2015
Source: EvaluatePharma, data retrieved January 21, 2011

03 The Global Diabetes Care Market CMD2011

Transféré par

Informations du document

Description originale:

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

03 The Global Diabetes Care Market CMD2011

Transféré par

Droits d'auteur :

Formats disponibles

Novo Nordisk Capital Markets Day

The global diabetes care market

Novo Nordisk Capital Markets Day

Novo Nordisk Capital Markets Day

18.4% 15.9% 12.3% 10.7% 12.0% 9.2% 6.4% 3.6% 7.8%

Source: EvaluatePharma, data retrieved January 21, 2011

Novo Nordisk Capital Markets Day

Diabetes market development

Global insulin market by segments

Total market: CAGR 11.4% Injectables: CAGR 15.6%

CAGR volume: 7.1% CAGR value*: 14.3% 34%

Fast acting 31% Premix 35% 30%

Note: *in DKK. Monthly MAT, volume figures Source: IMS

Novo Nordisk Capital Markets Day

Sustained double-digit insulin market growth

20.7 bDKK 21.6 bDKK 44.4 bDKK

Value Conversion to new generations of insulin Device penetration Price changes

Source: IMS, Monthly MAT, value figures

Novo Nordisk Capital Markets Day

Diagnosis and optimal treatment remains a challenge the rule of halves

450 400 350 300 250 200 150 100 50 0

All people with diabetes

50% are diagnosed

50% reach target

Novo Nordisk Capital Markets Day

The world is growing unhealthier

Proportion of overweight and obese of population (%)

United States Canada England France Italy

Novo Nordisk Capital Markets Day

Source: www.nationmaster.com, CIA world fact book

Novo Nordisk Capital Markets Day

82 years? 69 years 56 years

Source: www.nationmaster.com, CIA world fact book

Novo Nordisk Capital Markets Day

Implied development in insulin consumption

426 349 293

165 99 53 1 2000 2010 14

Novo Nordisk Capital Markets Day

Source: IMS, annual volume figures

Novo Nordisk Capital Markets Day

Human insulin Human insulin

Animal insulin Animal insulin

Source: IMS, monthly MAT value figures

Novo Nordisk Capital Markets Day

Two-thirds of insulin volume is injected via a modern pen device

Vial and syringe

Source: IMS, annual volume figures

Novo Nordisk Capital Markets Day

Characteristics of the insulin industry

Novo Nordisk Capital Markets Day

Novo Nordisk device development for improved insulin treatment

Novo Nordisk Capital Markets Day

Diabetes is chronic disease leading to long patient-drug relationship

Average life expectancy with type 2 diabetes

Diagnosis of type 2 diabetes

Novo Nordisk Capital Markets Day

North America: ~4,000 FTEs

Europe: ~3,100 FTEs

Japan & Korea: ~900 FTEs

China: ~2,100 FTEs

International Operations: ~2,700 FTEs

Novo Nordisk Capital Markets Day